scholarly journals PMDA's Initiatives Based on Regulatory Science. In Pursuit of Developing Innovative Drugs and Medical Devices

Author(s):  
Tatsuya Kondo
2020 ◽  
Vol 41 (1) ◽  
pp. 94-120 ◽  
Author(s):  
Mehdi Kazemzadeh-Narbat ◽  
Hao Cheng ◽  
Rosa Chabok ◽  
Mario Moisés Alvarez ◽  
Cesar de la Fuente-Nunez ◽  
...  

2015 ◽  
Vol 65 (4) ◽  
pp. 400-403 ◽  
Author(s):  
Christopher G. Scully ◽  
Shawn Forrest ◽  
Loriano Galeotti ◽  
Suzanne B. Schwartz ◽  
David G. Strauss

2018 ◽  
Vol 11 (1) ◽  
pp. 307-327 ◽  
Author(s):  
Yi Wang ◽  
Allan Guan ◽  
Samanthi Wickramasekara ◽  
K. Scott Phillips

In the United States, regulatory science is the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of all Food and Drug Administration–regulated products. Good regulatory science facilitates consumer access to innovative medical devices that are safe and effective throughout the Total Product Life Cycle (TPLC). Because the need to measure things is fundamental to the regulatory science of medical devices, analytical chemistry plays an important role, contributing to medical device technology in two ways: It can be an integral part of an innovative medical device (e.g., diagnostic devices), and it can be used to support medical device development throughout the TPLC. In this review, we focus on analytical chemistry as a tool for the regulatory science of medical devices. We highlight recent progress in companion diagnostics, medical devices on chips for preclinical testing, mass spectrometry for postmarket monitoring, and detection/characterization of bacterial biofilm to prevent infections.


2018 ◽  
Vol 2 (5) ◽  
pp. 301-304 ◽  
Author(s):  
Joan E. Adamo ◽  
Warren L. Grayson ◽  
Heather Hatcher ◽  
Jennifer Swanton Brown ◽  
Andrika Thomas ◽  
...  

Rapidly advancing technology often pulls the regulatory field along as it evolves to incorporate new concepts, better tools, and more finely honed equipment. When the area impacted by the technological advancement is regulated by the Food and Drug Administration (FDA), a gap develops between the technology and the guidelines that govern its application. Subsequently, there are challenges in determining appropriate regulatory pathways for evolving products at the initial research and developmental stages. Myriad factors necessitate several rounds of iterative review and the involvement of multiple divisions within the FDA. To better understand the regulatory science issues roiling around the area of additive manufacturing of medical products, a group of experts, led by a Clinical and Translational Science Award working group, convened the Regulatory Science to Advance Precision Medicine at the Fall Forum to discuss some of the current regulatory science roadblocks.


Sign in / Sign up

Export Citation Format

Share Document